CLIN.L - Clinigen Group Plc

LSE - LSE Delayed price. Currency in GBp
883.50
-22.50 (-2.48%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close906.00
Open900.00
Bid0.00 x 384900
Ask920.00 x 30000
Day's range882.50 - 903.50
52-week range807.50 - 1,187.00
Volume570,987
Avg. volume377,706
Market cap1.08B
Beta0.80
PE ratio (TTM)78.88
EPS (TTM)11.20
Earnings date13 Mar 2018 - 19 Mar 2018
Forward dividend & yield0.04 (0.38%)
Ex-dividend dateN/A
1y target est1,229.17
  • Business Wire2 months ago

    Clinigen Group Plc: Good H1 Performance with Adjusted EPS up 13%

    BURTON-ON-TRENT, England--(BUSINESSWIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six ...

  • Business Wire2 months ago

    Clinigen Group Plc: Good H1 Performance with Adjusted EPS up 13%

    Clinigen Group plc , the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2017.

  • Business Wire2 months ago

    Clinigen and Santhera Launch US Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy

    BURTON ON TRENT, England--(BUSINESSWIRE)-- Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has initiated an Expanded Access Program (‘EAP’) in the US with Santhera ...

  • Business Wire2 months ago

    Clinigen and Santhera Launch US Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy

    Clinigen Group plc , the global pharmaceutical and services company, has initiated an Expanded Access Program in the US with Santhera Pharmaceuticals for idebenone in patients with Duchenne Muscular Dystrophy who are in respiratory decline.

  • Business Wire5 months ago

    Clinigen Registers Garsun® (artesunate for injection) in South Africa for the Treatment of Patients with Severe Malaria

    Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that it has registered Garsun® (artesunate for injection) in South Africa. Equity Pharmaceutical (Pty) Ltd, a division of Clinigen, will be the Holder of the Certificate of Registration. Garsun® is an innovative medicine indicated for the treatment of severe malaria, specifically caused by the parasite Plasmodium falciparum, in both adults and children.

  • PR Newswire5 months ago

    Neuberger Berman Group LLC - Form 8.3 - Clinigen Group PLC

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • PR Newswire6 months ago

    Miton Group Plc - Form 8.3 - Clinigen Group Plc

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • PR Newswire6 months ago

    Neuberger Berman Group LLC - Form 8.3 - Clinigen Group PLC

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines

    BURTON-ON-TRENT, England--(BUSINESSWIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has today acquired International Medical Management ...

  • Business Wire6 months ago

    Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines

    Clinigen Group plc , the global pharmaceutical and services company, has today acquired International Medical Management Corporation , Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group plc

    LONDON--(BUSINESSWIRE)-- Form 8.3 August 2016 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group Plc

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Business Wire6 months ago

    Form 8.3 - Clinigen Group PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes